isoSolutions Marketing & Management Inc. offers a wide range of products for nuclear medicine applications, from a variety of reliable suppliers, providing a one-stop shopping service as well as technical support.
worldwide in 2017
on time in 2017
Posted by David T. Drummond ⎜ Nov 20, 2018
The worldwide supply of molybdenum-99 is expected to stabilize over the next several weeks as the High Flux Reactor in the Netherlands and the Open Pool Australian Lightwater nuclear reactor have resumed operations and are expected to reach normal Mo-99 production this week. Meanwhile, NTP Radioisotopes’ South Africa-based Pelindaba Nuclear Plant, which has finished functionality tests, is awaiting approval from the country’s National Nuclear Regulator to begin Mo-99 production runs.
Posted by David T. Drummond ⎜ Nov 19, 2018
An agreement signed with SpectronRx, an Indiana, USA radiopharmaceutical manufacturer, designates isoSolutions as the exclusive distributor in Latin America and Canada of Spectron’s GMP grade non-carrier added (nca) Lutetium-177 radiochemical.
Non-carrier added (nca) Lutetium-177 (Lu-177) is a radioisotope used for therapeutic purposes. …
SNMMI 2019 Annual Meeting, June 22-25, 2019 in Anaheim, California. isoSolutions is pleased to inform you that we will attend the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
isoSolutions will be attending the United Pharmacy Partners (UPPI, LLC) 2018 Annual Meeting to be held in San Antonio, TX September 12 to 15, 2018.
The Chinese Society of Nuclear Medicine Annual Meeting will be held in Chengdu, Sichuan from 2018–07–12 to 2018–07–15. We hope to see you there and we can arrange a time and place to meet if you wish.